- Home
- BIIB vs TEF Comparison
BIIB vs TEF Comparison
Compare BIIB & TEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TEF
- Stock Information
- Founded
- BIIB 1978
- TEF 1924
- Country
- BIIB United States
- TEF Spain
- Employees
- BIIB N/A
- TEF N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TEF Telecommunications Equipment
- Sector
- BIIB Health Care
- TEF Telecommunications
- Exchange
- BIIB Nasdaq
- TEF Nasdaq
- Market Cap
- BIIB 18.8B
- TEF 29.9B
- IPO Year
- BIIB 1991
- TEF 1987
- Fundamental
- Price
- BIIB $133.19
- TEF $5.33
- Analyst Decision
- BIIB Buy
- TEF
- Analyst Count
- BIIB 27
- TEF 0
- Target Price
- BIIB $188.17
- TEF N/A
- AVG Volume (30 Days)
- BIIB 1.3M
- TEF 550.8K
- Earning Date
- BIIB 07-31-2025
- TEF 07-30-2025
- Dividend Yield
- BIIB N/A
- TEF 4.39%
- EPS Growth
- BIIB 26.39
- TEF N/A
- EPS
- BIIB 10.12
- TEF N/A
- Revenue
- BIIB $9,816,400,000.00
- TEF $44,356,895,792.00
- Revenue This Year
- BIIB N/A
- TEF N/A
- Revenue Next Year
- BIIB N/A
- TEF $0.17
- P/E Ratio
- BIIB $13.16
- TEF N/A
- Revenue Growth
- BIIB 1.59
- TEF 0.72
- 52 Week Low
- BIIB $110.04
- TEF $3.89
- 52 Week High
- BIIB $238.00
- TEF $5.48
- Technical
- Relative Strength Index (RSI)
- BIIB 60.40
- TEF 58.53
- Support Level
- BIIB $123.90
- TEF $5.17
- Resistance Level
- BIIB $134.75
- TEF $5.24
- Average True Range (ATR)
- BIIB 3.53
- TEF 0.06
- MACD
- BIIB 0.04
- TEF -0.01
- Stochastic Oscillator
- BIIB 86.48
- TEF 54.55
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TEF Telefonica SA
Telefonica operates mobile and fixed networks in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.